JP2011519893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519893A5 JP2011519893A5 JP2011507898A JP2011507898A JP2011519893A5 JP 2011519893 A5 JP2011519893 A5 JP 2011519893A5 JP 2011507898 A JP2011507898 A JP 2011507898A JP 2011507898 A JP2011507898 A JP 2011507898A JP 2011519893 A5 JP2011519893 A5 JP 2011519893A5
- Authority
- JP
- Japan
- Prior art keywords
- particulate carrier
- bioactive agent
- polymer
- nanoparticles
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000969 carrier Substances 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 230000000975 bioactive Effects 0.000 claims 12
- 229920000642 polymer Polymers 0.000 claims 7
- 239000002105 nanoparticle Substances 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 claims 2
- 239000012074 organic phase Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 229920000936 Agarose Polymers 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (23)
- 微粒子担体の製造方法であって、以下のステップ:
a) ポリブチルシアノアクリレート(PBCA)を有機溶媒に溶解してポリマー溶液を形成するステップ;
b) 生物活性薬を含有する水溶液を該ポリマー溶液に加え、連続有機相中に水滴の一次乳濁液を形成するステップ;
c) 該一次乳濁液を水媒質と混合して二次乳濁液を形成するステップ;および
d) 有機相を蒸発させ、それによって生物活性薬を水相中に含有する中空内腔を含む微粒子担体を得るステップ、
を含む、上記方法。 - ステップ(a)がさらに、ゲル形成剤の添加を含む、請求項1に記載の方法。
- ゲル形成剤がアガロースである、請求項2に記載の方法。
- ポリマーがペグ化されている、請求項1〜3のいずれか1項に記載の方法。
- 微粒子担体がミクロスフェアである、請求項1〜4のいずれか1項に記載の方法。
- 微粒子担体がナノ粒子である、請求項1〜4のいずれか1項に記載の方法。
- 生物活性薬がタンパク質またはペプチドである、請求項1〜6のいずれか1項に記載の方法。
- 生物活性薬が抗原結合分子である、請求項7に記載の方法。
- 生物活性薬がドメインを含む、請求項8に記載の方法。
- 生物活性薬が抗体である、請求項9に記載の方法。
- 生物活性薬がドメイン抗体である、請求項9に記載の方法。
- 請求項1〜11のいずれか1項に記載の方法で得られた封入された生物活性薬を含む微粒子担体。
- 微粒子担体がナノ粒子である、請求項12に記載の微粒子担体。
- 生物活性薬がタンパク質である、請求項13に記載の微粒子担体。
- ナノ粒子中タンパク質のポリマーに対する比が少なくとも約5% w/w、少なくとも約10% w/wまたは少なくとも約14% w/wである、請求項14に記載の微粒子担体。
- 生物活性薬がペプチドである、請求項13に記載の微粒子担体。
- ナノ粒子中ペプチドのポリマーに対する比が少なくとも約5%w/wまたは少なくとも約10% w/wである、請求項16に記載の微粒子担体。
- 生物活性薬が抗体である、請求項13に記載の微粒子担体。
- ナノ粒子中抗体のポリマーに対する比が少なくとも約5% w/wまたは少なくとも約10% w/wである、請求項18に記載の微粒子担体。
- 生物活性薬がdAbである、請求項13に記載の微粒子担体。
- ナノ粒子中dAbのポリマーに対する比が少なくとも約5%w/w、少なくとも約10%w/wまたは少なくとも約14% w/wである、請求項20に記載の微粒子担体。
- 請求項12〜21のいずれか1項に記載の微粒子担体を含む医薬組成物。
- 疾患の治療または予防における請求項22に記載の組成物の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5077508P | 2008-05-06 | 2008-05-06 | |
US61/050,775 | 2008-05-06 | ||
US7417108P | 2008-06-20 | 2008-06-20 | |
US61/074,171 | 2008-06-20 | ||
PCT/EP2009/055437 WO2009135854A2 (en) | 2008-05-06 | 2009-05-05 | Encapsulation of biologically active agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011519893A JP2011519893A (ja) | 2011-07-14 |
JP2011519893A5 true JP2011519893A5 (ja) | 2012-02-09 |
Family
ID=43125568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011507898A Pending JP2011519893A (ja) | 2008-05-06 | 2009-05-05 | 生物活性薬の封入 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110059167A1 (ja) |
EP (1) | EP2271324A2 (ja) |
JP (1) | JP2011519893A (ja) |
CN (1) | CN102083423A (ja) |
AU (1) | AU2009245785A1 (ja) |
BR (1) | BRPI0912536A2 (ja) |
EA (1) | EA201001567A1 (ja) |
IL (1) | IL208666A0 (ja) |
MX (1) | MX2010012141A (ja) |
WO (1) | WO2009135854A2 (ja) |
ZA (1) | ZA201007437B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009245783A1 (en) * | 2008-05-06 | 2009-11-12 | Glaxo Group Limited | Encapsulation of biologically active agents |
WO2014197892A1 (en) | 2013-06-07 | 2014-12-11 | The Johns Hopkins University | A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases |
MA44323A (fr) * | 2015-11-20 | 2018-09-26 | Abbvie Deutschland | Nanosphères à surface modifiée encapsulant des molécules liant l'antigène |
US11491114B2 (en) * | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017789A1 (en) * | 1993-02-15 | 1994-08-18 | Shield Research Limited | Polyalkylcyanoacrylate nanocapsules |
ATE197124T1 (de) * | 1993-09-09 | 2000-11-15 | Schering Ag | Wirkstoffe und gas enthaltende mikropartikel |
EP0975334B1 (en) * | 1997-04-17 | 2003-10-22 | Amgen Inc., | Biodegradable microparticles for the sustained delivery of therapeutic drugs |
US20030152636A1 (en) * | 2000-02-23 | 2003-08-14 | Nanopharm Ag | Method of treating cancer |
US7332159B2 (en) * | 2004-09-30 | 2008-02-19 | Board Of Regents Of The University Of Nebraska | Method and composition for inhibiting reperfusion injury in the brain |
US7597907B2 (en) * | 2004-11-05 | 2009-10-06 | Trustees Of The University Of Pennsylvania | Antioxidant polymer nanocarriers for use in preventing oxidative injury |
-
2009
- 2009-05-05 JP JP2011507898A patent/JP2011519893A/ja active Pending
- 2009-05-05 US US12/991,521 patent/US20110059167A1/en not_active Abandoned
- 2009-05-05 BR BRPI0912536A patent/BRPI0912536A2/pt not_active Application Discontinuation
- 2009-05-05 CN CN2009801270058A patent/CN102083423A/zh active Pending
- 2009-05-05 MX MX2010012141A patent/MX2010012141A/es unknown
- 2009-05-05 EP EP09742072A patent/EP2271324A2/en not_active Withdrawn
- 2009-05-05 EA EA201001567A patent/EA201001567A1/ru unknown
- 2009-05-05 AU AU2009245785A patent/AU2009245785A1/en not_active Abandoned
- 2009-05-05 WO PCT/EP2009/055437 patent/WO2009135854A2/en active Application Filing
-
2010
- 2010-10-12 IL IL208666A patent/IL208666A0/en unknown
- 2010-10-18 ZA ZA2010/07437A patent/ZA201007437B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mikušová et al. | Advances in chitosan-based nanoparticles for drug delivery | |
Leyva-Gómez et al. | Approaches in polymeric nanoparticles for vaginal drug delivery: a review of the state of the art | |
Arya et al. | Assessing the viability of microsponges as gastro retentive drug delivery system of curcumin: optimization and pharmacokinetics | |
Hao et al. | Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery | |
Wang et al. | Facile synthesis of uniform virus-like mesoporous silica nanoparticles for enhanced cellular internalization | |
Zhou et al. | Construction of silica‐based micro/nanoplatforms for ultrasound theranostic biomedicine | |
Roggers et al. | The practicality of mesoporous silica nanoparticles as drug delivery devices and progress toward this goal | |
US20210093580A1 (en) | Nanoscale coatings for encapsulation of biological entities | |
JP6092121B2 (ja) | 疎水性分子に誘起された分岐ポリマー凝集体及びその使用 | |
Dimer et al. | Inhalable resveratrol microparticles produced by vibrational atomization spray drying for treating pulmonary arterial hypertension | |
Feitosa et al. | Pharmacokinetic aspects of nanoparticle-in-matrix drug delivery systems for oral/buccal delivery | |
Jain et al. | Montmorillonite-PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride | |
Zhang et al. | Nanoscale bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates for selective cancer therapy | |
JP2010513363A5 (ja) | ||
CN102016814A (zh) | 纳米粒子制备方法、系统及材料 | |
JP2011519932A5 (ja) | ||
KR20090113852A (ko) | 암 치료용 제제 | |
Ahmad et al. | Silymarin: an insight to its formulation and analytical prospects | |
Kim et al. | Comparison of three different aqueous microenvironments for enhancing oral bioavailability of sildenafil: solid self-nanoemulsifying drug delivery system, amorphous microspheres and crystalline microspheres | |
JP2011519893A5 (ja) | ||
Hanna et al. | Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption | |
Ucar et al. | A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2 | |
JP2011225600A5 (ja) | ||
US10034837B2 (en) | Nanoparticle drug delivery | |
Das et al. | Stimuli-responsive boron-based materials in drug delivery |